Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
Go back to Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology| (NASDAQ: NRIX) | Delayed: 26.13 -0.01 (0.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $26.14 | 52 Week High | $ | |||
| Open | $25.42 | 52 Week Low | $ | |||
| Day High | $26.42 | P/E | N/A | |||
| Day Low | $25.36 | EPS | $ | |||
| Volume | 1,287,863 | |||||
